Is culture-free pneumonia testing finally viable as Pattern Bioscience nears regulatory submission
Pattern Bioscience advances rapid pneumonia diagnostics toward FDA clearance. Discover what this means for ICU care and antibiotic resistance.
Intelligent Bio Solutions taps Syrma Johari to cut drug reader costs and prep for U.S. launch
INBS teams up with Syrma Johari to cut device costs, expand global output, and prep for a 2026 U.S. launch. Find out what this changes for fingerprint drug testing.